ATHA
Closed
Athira Pharma inc
0.3
0.0 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 0.302
Day's Range: 0.2854 - 0.3127
Send
sign up or login to leave a comment!
When Written:
2.5
Athira Pharma Inc is a clinical-stage biopharmaceutical company that is focused on developing innovative therapies for neurodegenerative diseases. The company is headquartered in Seattle, Washington and was founded in 2011 by Dr. Leen Kawas.
Athira Pharma is developing a new class of regenerative therapeutics that target the underlying pathology of Alzheimer's and other neurodegenerative diseases. The company's lead product candidate, ATH-1017, is a small molecule drug that is designed to enhance the activity of HGF/MET, a growth factor that plays a critical role in brain function and repair.
The company has completed a Phase 1 clinical trial of ATH-1017, which demonstrated safety and tolerability in healthy volunteers. Athira Pharma is currently conducting a Phase 2 clinical trial of ATH-1017 in patients with Alzheimer's disease.
Athira Pharma has raised over $300 million in funding from investors, including Perceptive Advisors, Viking Global Investors, and Venrock. The company went public in September 2020, raising $204 million in its initial public offering (IPO).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Athira Pharma is developing a new class of regenerative therapeutics that target the underlying pathology of Alzheimer's and other neurodegenerative diseases. The company's lead product candidate, ATH-1017, is a small molecule drug that is designed to enhance the activity of HGF/MET, a growth factor that plays a critical role in brain function and repair.
The company has completed a Phase 1 clinical trial of ATH-1017, which demonstrated safety and tolerability in healthy volunteers. Athira Pharma is currently conducting a Phase 2 clinical trial of ATH-1017 in patients with Alzheimer's disease.
Athira Pharma has raised over $300 million in funding from investors, including Perceptive Advisors, Viking Global Investors, and Venrock. The company went public in September 2020, raising $204 million in its initial public offering (IPO).
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!